drugset / Trial / NCT04410796
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Phase 2
Recruiting
571 enrolled
Memorial Sloan Kettering Cancer Center
AstraZeneca · collabGuardant Health, Inc. · collab
RandomizedCrossoverOpen-labelTreatment
Summary
This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.
Timeline
- Start
- 2020-05-28
- Primary completion
- 2027-05
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
| Background | Osimertinib | Small molecule | 80 mg | Oral |